Status:
TERMINATED
Effect Of GW501516X On How The Heart Obtains And Uses Energy
Lead Sponsor:
GlaxoSmithKline
Conditions:
Dyslipidaemias
Heart Failure
Eligibility:
MALE
18-40 years
Brief Summary
The purpose of this study is to determine the effect of a 4-week treatment period with GW501516X on how the heart obtains and uses energy. The energy of the heart will be measured by Magnetic Resonanc...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Non-smoking.
- Body Mass Index of greater than 27 and less than 32 and who weigh 120 kg (264 lbs) or less and have a waist circumference of greater than 95 cm (37.5 inches).
- Exclusion criteria:
- History of muscle disease, coagulation disorders, heart disease or abnormal heart rhythm (or a family history of early coronary artery disease).
- Documented diabetes, hypoglycemia, thyroid disfunction or adrenal disorder.
Exclusion
Key Trial Info
Start Date :
December 1 2005
Trial Type :
OBSERVATIONAL
End Date :
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00318617
Start Date
December 1 2005
Last Update
March 19 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19104